Diagnosis and Management of Ischemic Stroke

  • Aslam M. Khaja
Part of the Contemporary Cardiology book series (CONCARD)


Until 1995, ischemic stroke management was a classic example of “diagnose and adios.” Care of patients presenting to the hospital or clinic with symptoms of stroke consisted of aspirin followed by rehabilitation, with few disease-specific strategies directed toward optimal treatment and outcomes. The past two decades have witnessed an explosion of research into ischemic stroke. We now have specific therapies and management strategies to reduce morbidity and mortality. This chapter will first discuss the identification of patients with ischemic stroke, followed by acute treatment, inpatient management, and secondary stroke prevention.


Stroke Stent Lesion Treatment Edema 


  1. 1.
    Adams HP Jr, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38(5):1655–711.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Frankel MR, et al. Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology. 2000;55(7):952–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Khaja AM, Grotta JC. Established treatments for acute ischaemic stroke. Lancet. 2007;369(9558):319–30.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Adams HP Jr, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34(4):1056–83.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Sarikaya H, et al. Different pattern of clinical deficits in stroke mimics treated with intravenous thrombolysis. Eur Neurol. 2012;68(6):344–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hand PJ, et al. Distinguishing between stroke and mimic at the bedside: the brain attack study. Stroke. 2006;37(3):769–75.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Libman RB, et al. Conditions that mimic stroke in the emergency department. Implications for acute stroke trials. Arch Neurol. 1995;52(11):1119–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Muir KW, et al. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke. 1996;27(10):1817–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Jacobs L, Kinkel WR, Heffner RR Jr. Autopsy correlations of computerized tomography: experience with 6,000 CT scans. Neurology. 1976;26(12):1111–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Mullins ME, et al. CT and conventional and diffusion-weighted MR imaging in acute stroke: study in 691 patients at presentation to the emergency department. Radiology. 2002;224(2):353–60.CrossRefPubMedGoogle Scholar
  11. 11.
    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7.CrossRefGoogle Scholar
  12. 12.
    Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol. 2004;61(7):1066–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Khaja AM. Acute ischemic stroke management: administration of thrombolytics, neuroprotectants, and general principles of medical management. Neurol Clin. 2008;26(4):943–61. viiiCrossRefPubMedGoogle Scholar
  14. 14.
    Katzan IL, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000;283(9):1151–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Katzan IL, et al. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke. 2003;34(3):799–800.CrossRefPubMedGoogle Scholar
  16. 16.
    Barber PA, et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56(8):1015–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Hacke W, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–74.CrossRefPubMedGoogle Scholar
  18. 18.
    Hacke W, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.CrossRefPubMedGoogle Scholar
  19. 19.
    Jauch EC, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.CrossRefGoogle Scholar
  20. 20.
    Demaerschalk BM, et al. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016;47(2):581–641.CrossRefGoogle Scholar
  21. 21.
    Qureshi AI. Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet. 2004;363(9411):804–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Kidwell CS, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368(10):914–23.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ciccone A, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368(10):904–13.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Broderick JP, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893–903.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Saver JL, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372(24):2285–95.CrossRefPubMedGoogle Scholar
  26. 26.
    Jovin TG, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296–306.CrossRefPubMedGoogle Scholar
  27. 27.
    Goyal M, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019–30.CrossRefGoogle Scholar
  28. 28.
    Campbell BC, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009–18.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Berkhemer OA, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11–20.CrossRefGoogle Scholar
  30. 30.
    Powers WJ, et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(10):3020–35.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Hacke W, Krieger D, Hirschberg M. General principles in the treatment of acute Ishemic stroke. Cerebrovasc Dis. 1991;1(suppl 1):93–9.CrossRefGoogle Scholar
  32. 32.
    Ronning OM, Guldvog B. Should stroke victims routinely receive supplemental oxygen? A quasi-randomized controlled trial. Stroke. 1999;30(10):2033–7.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    ECC Committee, Subcommittees and task forces of the American Heart Association. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005;112(24 Suppl):IV1–203.Google Scholar
  34. 34.
    Haddah SH, Arabi YM. A review of the scientific evidence on the treatment of traumatic brain injuries and strokes with hyperbaric oxygen. Brain Inj. 2003;17(3):225–36.CrossRefGoogle Scholar
  35. 35.
    Azzimondi G, et al. Fever in acute stroke worsens prognosis. A prospective study. Stroke. 1995;26(11):2040–3.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Hajat C, Hajat S, Sharma P. Effects of poststroke pyrexia on stroke outcome : a meta-analysis of studies in patients. Stroke. 2000;31(2):410–4.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Jorgensen HS, et al. What determines good recovery in patients with the most severe strokes? The Copenhagen Stroke Study. Stroke. 1999;30(10):2008–12.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Bernard SA, Gray TW, Buist MD, et al. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549–56.CrossRefGoogle Scholar
  39. 39.
    Bernard SA, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346(8):557–63.CrossRefGoogle Scholar
  40. 40.
    Krieger DW, et al. Cooling for acute ischemic brain damage (cool aid): an open pilot study of induced hypothermia in acute ischemic stroke. Stroke. 2001;32(8):1847–54.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Wang H, et al. Rapid and selective cerebral hypothermia achieved using a cooling helmet. J Neurosurg. 2004;100(2):272–7.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Slotboom J, et al. Locally induced hypothermia for treatment of acute ischaemic stroke: a physical feasibility study. Neuroradiology. 2004;46(11):923–34.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Martin-Schild S, et al. Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke: a pilot study of caffeinol and mild hypothermia. J Stroke Cerebrovasc Dis. 2009;18(2):86–96.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Olsen TS, Weber UJ, Kammersgaard LP. Therapeutic hypothermia for acute stroke. Lancet Neurol. 2003;2(7):410–6.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Kocan MJ. Cardiovascular effects of acute stroke. Prog Cardiovasc Nurs. 1999;14(2):61–7.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Korpelainen JT, et al. Abnormal heart rate variability as a manifestation of autonomic dysfunction in hemispheric brain infarction. Stroke. 1996;27(11):2059–63.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Orlandi G, et al. Transient autonomic nervous system dysfunction during hyperacute stroke. Acta Neurol Scand. 2000;102(5):317–21.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Afsar N, et al. Acute stroke increases QT dispersion in patients without known cardiac diseases. Arch Neurol. 2003;60(3):346–50.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    McDermott MM, et al. ST segment depression detected by continuous electrocardiography in patients with acute ischemic stroke or transient ischemic attack. Stroke. 1994;25(9):1820–4.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Sacco RL, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37(2):577–617.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Vemmos KN, et al. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med. 2004;255(2):257–65.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Johnston KC, Mayer SA. Blood pressure reduction in ischemic stroke: a two-edged sword? Neurology. 2003;61(8):1030–1.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Goldstein LB. Blood pressure management in patients with acute ischemic stroke. Hypertension. 2004;43(2):137–41.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Martin-Schild S. Blood pressure in acute stroke: lower it or let the CHHIPS fall where they will. Lancet Neurol. 2009;8(1):23–4.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Potter JF, et al. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol. 2009;8(1):48–56.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28(11):2109–18.CrossRefGoogle Scholar
  57. 57.
    Larrue V, et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997;28(5):957–60.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Bruno A, et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology. 1999;52(2):280–4.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. Stroke. 2004;35(2):363–4.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Candelise L, et al. Prognostic significance of hyperglycemia in acute stroke. Arch Neurol. 1985;42(7):661–3.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Griesdale DE, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. Cmaj. 2009;180(8):821–7.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Finfer S, Heritier S. The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) Study: statistical analysis plan. Crit Care Resusc. 2009;11(1):46–57.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Levetan CS. Effect of hyperglycemia on stroke outcomes. Endocr Pract. 2004;10(Suppl 2):34–9.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Roberts TP, Rowley HA. Diffusion weighted magnetic resonance imaging in stroke. Eur J Radiol. 2003;45(3):185–94.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Thulborn KR. MRI in the management of cerebrovascular disease to prevent stroke. Neurol Clin. 2008;26(4):897–921. vii-viiiCrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Atlas SW, Thulborn KR. MR detection of hyperacute parenchymal hemorrhage of the brain. AJNR Am J Neuroradiol. 1998;19(8):1471–7.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Gomori JM, Grossman RI. Mechanisms responsible for the MR appearance and evolution of intracranial hemorrhage. Radiographics. 1988;8(3):427–40.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Grant EG, et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis--Society of Radiologists in Ultrasound Consensus Conference. Radiology. 2003;229(2):340–6.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Koelemay MJ, et al. Systematic review of computed tomographic angiography for assessment of carotid artery disease. Stroke. 2004;35(10):2306–12.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Jaff MR, et al. Imaging of the carotid arteries: the role of duplex ultrasonography, magnetic resonance arteriography, and computerized tomographic arteriography. Vasc Med. 2008;13(4):281–92.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Homma S. Echocardiography in stroke patients (with emphasis on cryptogenic stroke). Rinsho Shinkeigaku. 2006;46(11):799–804.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Ropper AH, Shafran B. Brain edema after stroke. Clinical syndrome and intracranial pressure. Arch Neurol. 1984;41(1):26–9.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Wijdicks EF, Diringer MN. Middle cerebral artery territory infarction and early brain swelling: progression and effect of age on outcome. Mayo Clin Proc. 1998;73(9):829–36.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Vahedi K, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6(3):215–22.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Hofmeijer J, et al. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol. 2009;8(4):326–33.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Kilpatrick CJ, et al. Epileptic seizures in acute stroke. Arch Neurol. 1990;47(2):157–60.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Lawes CM, et al. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35(3):776–85.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. 2003;34(11):2741–8.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304–9.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Patel A, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRefPubMedGoogle Scholar
  81. 81.
    Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRefGoogle Scholar
  82. 82.
    Duckworth W, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.CrossRefGoogle Scholar
  83. 83.
    Gorelick PB. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. Stroke. 2002;33(3):862–75.CrossRefPubMedGoogle Scholar
  84. 84.
    Amarenco P, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–59.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Stone NJ, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.CrossRefGoogle Scholar
  86. 86.
    Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989;298(6676):789–94.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    He J, et al. Passive smoking and the risk of coronary heart disease--a meta-analysis of epidemiologic studies. N Engl J Med. 1999;340(12):920–6.CrossRefPubMedGoogle Scholar
  88. 88.
    You RX, et al. Ischemic stroke risk and passive exposure to spouses' cigarette smoking. Melbourne Stroke Risk Factor Study (MERFS) Group. Am J Public Health. 1999;89(4):572–5.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Bonita R, et al. Passive smoking as well as active smoking increases the risk of acute stroke. Tob Control. 1999;8(2):156–60.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care. 2000;45(10):1200–62.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Wannamethee SG, et al. Smoking cessation and the risk of stroke in middle-aged men. JAMA. 1995;274(2):155–60.CrossRefPubMedGoogle Scholar
  92. 92.
    Kawachi I, et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. Ann Intern Med. 1993;119(10):992–1000.CrossRefPubMedGoogle Scholar
  93. 93.
    Reynolds K, et al. Alcohol consumption and risk of stroke: a meta-analysis. JAMA. 2003;289(5):579–88.CrossRefPubMedGoogle Scholar
  94. 94.
    Kurth T, et al. Body mass index and the risk of stroke in men. Arch Intern Med. 2002;162(22):2557–62.CrossRefPubMedGoogle Scholar
  95. 95.
    Lindenstrom E, Boysen G, Nyboe J. Lifestyle factors and risk of cerebrovascular disease in women. The Copenhagen City Heart Study. Stroke. 1993;24(10):1468–72.CrossRefPubMedGoogle Scholar
  96. 96.
    Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001;9(Suppl 4):326S–34S.CrossRefPubMedGoogle Scholar
  97. 97.
    Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Bmj. 1994;308(6921):81–106.CrossRefGoogle Scholar
  98. 98.
    The Dutch TIA Study Group. The Dutch TIA Trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke. 1988;19(4):512–7.CrossRefGoogle Scholar
  99. 99.
    Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj. 2002;324(7329):71–86.CrossRefGoogle Scholar
  100. 100.
    CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–39.CrossRefGoogle Scholar
  101. 101.
    Diener HC, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7.CrossRefPubMedGoogle Scholar
  102. 102.
    Diener HC, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13.CrossRefPubMedGoogle Scholar
  103. 103.
    Sacco RL, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238–51.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Kernan WN, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.CrossRefGoogle Scholar
  105. 105.
    Depta JP, et al. Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. Stroke. 2012;43(9):2376–81.CrossRefPubMedGoogle Scholar
  106. 106.
    Treiman GS, et al. Spontaneous dissection of the internal carotid artery: a nineteen-year clinical experience. J Vasc Surg. 1996;24(4):597–605. discussion 605-7CrossRefPubMedGoogle Scholar
  107. 107.
    Abbott AL, et al. Systematic Review of Guidelines for the Management of Asymptomatic and Symptomatic Carotid Stenosis. Stroke. 2015;46(11):3288–301.CrossRefPubMedGoogle Scholar
  108. 108.
    Brott TG, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1):11–23.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Chimowitz MI, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993–1003.CrossRefPubMedPubMedCentralGoogle Scholar
  110. 110.
    Chimowitz MI, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305–16.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449–57.Google Scholar
  112. 112.
    Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343(8899):687–91.Google Scholar
  113. 113.
    Healey JS, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke. 2008;39(5):1482–6.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Rizos T, et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke. 2012;43(10):2689–94.CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Flint AC, et al. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. Stroke. 2012;43(10):2788–90.CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Tayal AH, Callans DJ. Occult atrial fibrillation in ischemic stroke: seek and you shall find. Neurology. 2010;74(21):1662–3.CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Akins PT, et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke. 2007;38(3):874–80.CrossRefPubMedPubMedCentralGoogle Scholar
  118. 118.
    Lansberg MG, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e601S–36S.CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Holmes DR Jr, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65(24):2614–23.CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Reddy VY, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988–98.CrossRefPubMedGoogle Scholar
  121. 121.
    Holmes DR Jr, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1–12.CrossRefPubMedGoogle Scholar
  122. 122.
    Reddy VY, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61(25):2551–6.CrossRefPubMedGoogle Scholar
  123. 123.
    Connolly S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–12.CrossRefPubMedGoogle Scholar
  124. 124.
    EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342(8882):1255–62.CrossRefGoogle Scholar
  125. 125.
    Singer DE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):546s–92s.CrossRefPubMedGoogle Scholar
  126. 126.
    Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84(2):527–39.CrossRefGoogle Scholar
  127. 127.
    Connolly SJ, et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med. 2011;155(9):579–86.CrossRefPubMedGoogle Scholar
  128. 128.
    Connolly SJ, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–78.CrossRefPubMedGoogle Scholar
  129. 129.
    Davalos A, et al. Retrospective multicenter study of Solitaire FR for revascularization in the treatment of acute ischemic stroke. Stroke. 2012;43(10):2699–705.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Aslam M. Khaja
    • 1
  1. 1.NeurologyNorthwest Neurology, Ltd.South BarringtonUSA

Personalised recommendations